Alterity Therapeutics Announced That The Last Patient In The ATH434-201 Phase 2 Trial, A Randomized, Double-blind, Placebo-controlled Investigation In Early-stage Multiple System Atrophy, Has Completed The Study And Topline Results Are Expected To Be...

BenzingaDec 4 07:44 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaNov 29 16:06 ET

Alterity Therapeutics Alerts Investors on Potential Risks

TipRanksNov 21 17:37 ET

Alterity Therapeutics Advances in Neurodegenerative Drug Trials

TipRanksNov 21 17:37 ET

Alterity Therapeutics Appoints New Company Secretary

TipRanksNov 18 23:19 ET

Alterity Therapeutics Unveils New Advances for MSA Tracking

TipRanksNov 11 19:28 ET